New Delhi: Drug firm Panacea Biotec on Wednesday said its promoters have entered into a family agreement under which they plan to demerge the company’s real estate business into a separate firm to be later listed on bourses.
Under a memorandum of acknowledgment of oral family settlement, the promoters have decided that the company’s real estate arm, Radhika Heights Ltd, would be managed by Ravinder Jain and may become a separately listed entity, Panacea Biotec said in a filing to the BSE.
On the other hand, the pharmaceutical formulation and vaccine business will continue to be managed by promoters Soshil Kumar Jain, Rajesh Jain and Sandeep Jain, it added. This is being done to increase efficiency in management, control, and administration of the company and its subsidiaries and enhance stakeholders’ value, Panacea Biotec said.
“To enable the company to focus on its core business and raise necessary resources for respective businesses independently, the real estate business may be demerged into Radhika Heights Ltd, a separately listed company…,” it added.
The promoter group currently holds 74.6% stake in the company and the remaining 25.4% is with the public. The stock of Panacea Biotec jumped to Rs 172.90 in the afternoon trade on the BSE, sharply up 14.85% from the previous close.
Latest posts by Ruby Khatun (see all)
- JnJ faulty hip implants case: CIC directs RTI disclosure of records - September 10, 2018
- Max Bupa launches WeCare initiative to aid Kerala flood victims - September 10, 2018
- Opposing Online Pharmacies, 8.5 lakh chemists to call it a strike on September 28 - September 9, 2018